China Liver Cancer Clinical Registry Cohort Database (HEAL)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Procedure/Surgery treatment, Anti-Tumor Drugs.
- Who it may be relevant to
- Registry conditions: Liver Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.
Interventions
- Procedure Procedure/Surgery treatment
Routine surgical operations for patients with hepatocellular carcinoma, such as surgical resection, ablation，TACE，HAIC - Drug Anti-Tumor Drugs
Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs
Primary outcome measures
- OS [Time frame: 10 years]
Secondary outcome measures (2)
- RFS [Time frame: 10 years]
- Survival time after recurrence [Time frame: 10 years]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years, no gender limit
- Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests
- Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples
Exclusion criteria
- Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections
- Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication
- Pregnant or breastfeeding women
- Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 38 centers
- Anqing First People's Hospital — Anqing
- Anqing Municipal Hospital — Anqing
- Bengbu First People's Hospital — Bengbu
- The First Affiliated Hospital of Bengbu Medical University — Bengbu
- The Second Affiliated Hospital of Bengbu Medical College — Bengbu
- The People's Hospital of Bozhou — Bozhou
- The People's Hospital of Chizhou — Chizhou
- The First People's Hospital of Chuzhou — Chuzhou
- … and 30 more centers
Identifiers
NCT: NCT06777485 · 2024KY585